Supplementary file 3.pdf (2.72 MB)

Supplementary file 3: Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review

figure

posted on 2021-06-11, 10:49 authored by Xingyu LiuXingyu Liu, Huifang Xing, Hongbing Zhang, Hongyu Liu, Jun Chen

Supplementary Figures:

Figure S1. Trial Selection Process

Figure S2. Funnel Plot comparing the Hazard Ratios for Overall Survival and Progression-free Survival, and Risk Ratios for Objective Response Rate

Figure S3. Egger’s publication bias plot for Overall Survival (OS), Progression-free Survival (PFS) and Objective Response Rate (ORR)

Figure S4. Sensitivity analyses of Overall Survival (OS),Progression-free Survival (PFS) and Objective Response Rate (ORR) by repeating the pooled analyses with one study omitted at a time

Funding

This work was supported by grants from the National Natural Science Foundation of China (81773207), the Natural Science Foundation of Tianjin (17YFZCSY00840, 18PTZWHZ00240, 19YFZCSY00040), and the Special support program for High Tech Leader & Team of Tianjin (TJTZJH-GCCCXCYTD-2-6).

History

Usage metrics

Read the peer-reviewed publication

Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review

Immunotherapy

Keywords

Immune checkpoint inhibitor Chemotherapy programmed death 1 Programmed death 1 ligand 1 cytotoxic T-lymphocyte antigen-4 Extensive-Stage Small-Cell Lung Cancer Tumour Immunology Cancer Therapy (excl. Chemotherapy and Radiation Therapy)Chemotherapy

Licence

CC BY-NC-ND 4.0